Valneva SE (EPA: VLA)
France
· Delayed Price · Currency is EUR
1.924
-0.080 (-3.99%)
Dec 20, 2024, 5:35 PM CET
Valneva SE Employees
Valneva SE had 676 employees as of December 31, 2023. The number of employees decreased by 43 or -5.98% compared to the previous year.
Employees
676
Change (1Y)
-43
Growth (1Y)
-5.98%
Revenue / Employee
€234,519
Profits / Employee
€10,973
Market Cap
312.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 151,292 |
Eurofins Scientific SE | 61,798 |
Ipsen S.A. | 5,325 |
MedinCell S.A. | 134 |
ABIVAX Société Anonyme | 61 |
Eurobio Scientific Société anonyme | 300 |
Inventiva S.A. | 123 |
Cegedim SA | 6,582 |
Valneva SE News
- 2 days ago - Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - GlobeNewsWire
- 17 days ago - Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal - GlobeNewsWire
- 18 days ago - Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults - Benzinga
- 18 days ago - Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 25 days ago - Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - GlobeNewsWire
- 5 weeks ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 5 weeks ago - Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 6 weeks ago - Valneva SE (VALN) Q3 2024 Earnings Call Transcript - Seeking Alpha